Nuformix PLC (LSE:NFX) executive director Dr Dan Gooding speaks to Proactive shortly after releasing an update on the company's NXP004 programme, aimed at developing novel forms of AstraZeneca’s Olaparib (Lynparza) cancer drug.
Gooding reveals what investors can expect from Nuformix in 2023, saying that his aspiration is for data from the NXP002 programme to be supportive of the company "initiating discussions with major pharma."